REFERENCES
- de Lima MS, de Oliveira Soares BG, Reisser AA, Farrell M. Pharmacological treatment of cocaine dependence: A systematic review. Addict 2002; 97(8):931–949.
- Childress AR, O'Brien CP. Dopamine receptor partial agonists could address the duality of cocaine craving. Trends Pharmacol Sci 2000; 21(1):6–9.
- Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302(1):381–389.
- Stoops WW. Aripiprazole as a potential pharmacotherapy for stimulant dependence: Human laboratory studies with d-amphetamine. Exp Clin Psychopharmacol 2006; 14(4):413–421.
- Lile JA, Stoops WW, Vansickel AR, Glaser PE, Hays LR, Rush CR. Aripiprazole attenuates the discriminative-stimulus effects of d-amphetamine in humans. Neuropsychopharmacology 2005; 30(11):2103–2114.
- Stoops WW, Lile JA, Glaser PE, Rush CR. A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend 2006; 84(2):206–209.
- Oliveto AH, Bickel WK, Hughes JR, Shea PJ, Higgins ST, Fenwick JW. Caffeine drug discrimination in humans: Acquisition, specificity and correlation with self-reports. J Pharmacol Exp Ther 1992; 261(3):885–894.
- Dudish-Poulsen SA, Hatsukami DK. Dissociation between subjective and behavioral responses after cocaine stimuli presentations. Drug Alcohol Depend 1997; 47(1):1–9.
- Di Marino ME, Haberny KA, Felch LJ, Walsh SL, Preston KL, Bigelow GE. Development of a subject-rated rating scale sensitive to acute cocaine administration. In Problems of Drug Dependence, 1997: Proceedings of the 59th Annual Scientific Meeting. Harris L, ed. Rockville, MD: National Institute on Drug Abuse Research Monograph Series, 1998; 139.
- Rush CR, Stoops WW, Hays LR, Glaser PEA, Hays LS. Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J Pharmacol Exp Ther 2003; 306(1):195–204.
- Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672–676.
- Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334:1–100.
- Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988; 39(11):1172–1177.
- Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11–19.
- Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63(9):763–771.
- Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF. Aripiprazole in schizophrenia with cocaine dependence: A pilot study. J Clin Psychopharmacol 2005; 25(4):363–366.
- Brown ES, Jeffress J, Liggin JD, Garza M, Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 2005; 66(6):756–760.
- Tiihonen J, Kuoppasalmi K, Föhr J, Tuomola P, Kuikanmäki O, Vorma H, Sokero P, Haukka J, Meririnne E. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 2007; 164(1):160–162.